Oxyresveratrol Inhibits R848-Induced Pro-Inflammatory Mediators Release by Human Dendritic Cells Even When Embedded in PLGA Nanoparticles by Gaglio, Salvatore Calogero et al.
molecules
Article
Oxyresveratrol Inhibits R848-Induced Pro-Inflammatory
Mediators Release by Human Dendritic Cells Even When
Embedded in PLGA Nanoparticles
Salvatore Calogero Gaglio 1, Marta Donini 2 , Piyachat Evelyn Denbaes 1, Stefano Dusi 2,*
and Massimiliano Perduca 1,*


Citation: Gaglio, S.C.; Donini, M.;
Denbaes, P.E.; Dusi, S.; Perduca, M.
Oxyresveratrol Inhibits R848-Induced
Pro-Inflammatory Mediators Release
by Human Dendritic Cells Even
When Embedded in PLGA
Nanoparticles. Molecules 2021, 26,
2106. https://doi.org/10.3390/
molecules26082106
Academic Editors: Filomena Barreiro
and Isabel P. Fernandes
Received: 15 March 2021
Accepted: 3 April 2021
Published: 7 April 2021
Publisher’s Note: MDPI stays neutral
with regard to jurisdictional claims in
published maps and institutional affil-
iations.
Copyright: © 2021 by the authors.
Licensee MDPI, Basel, Switzerland.
This article is an open access article
distributed under the terms and
conditions of the Creative Commons
Attribution (CC BY) license (https://
creativecommons.org/licenses/by/
4.0/).
1 Department of Biotechnology, University of Verona, Strada Le Grazie 15, 37134 Verona, Italy;
salvatorecalogero.gaglio@univr.it (S.C.G.); pyachat@live.com (P.E.D.)
2 Department of Medicine, Section of General Pathology, University of Verona, Strada Le Grazie 8,
37134 Verona, Italy; marta.donini@univr.it
* Correspondence: stefano.dusi@univr.it (S.D.); massimiliano.perduca@univr.it (M.P.);
Tel.: +39-045-802-7124 (S.D.); +39-045-802-7984 (M.P.)
Abstract: Oxyresveratrol, a stilbene extracted from the plant Artocarpus lakoocha Roxb., has been
reported to provide a considerable anti-inflammatory activity. Since the mechanisms of this thera-
peutic action have been poorly clarified, we investigated whether oxyresveratrol affects the release of
the pro-inflammatory cytokines IL-12, IL-6, and TNF-α by human dendritic cells (DCs). We found
that oxyresveratrol did not elicit per se the release of these cytokines, but inhibited their secretion
induced upon DC stimulation with R848 (Resiquimod), a well-known immune cell activator engaging
receptors recognizing RNA viruses. We then investigated whether the inclusion of oxyresveratrol
into nanoparticles promoting its ingestion by DCs could favor its effects on cytokine release. For this
purpose we synthesized and characterized poly(lactic-co-glycolic acid) (PLGA) nanoparticles, and
we assessed their effects on DCs. We found that bare PLGA nanoparticles did not affect cytokine
secretion by resting DCs, but increased IL-12, IL-6, and TNF-α secretion by R848-stimulated DCs,
an event known as “priming effect”. We then loaded PLGA nanoparticles with oxyresveratrol and
we observed that oxyresveratrol-bearing particles did not stimulate the cytokine release by resting
DCs and inhibited the PLGA-dependent enhancement of IL-12, IL-6, and TNF-α secretion by R848-
stimulated DCs. The results herein reported indicate that oxyresveratrol suppresses the cytokine
production by activated DCs, thus representing a good anti-inflammatory and immune-suppressive
agent. Moreover, its inclusion into PLGA nanoparticles mitigates the pro-inflammatory effects due to
cooperation between nanoparticles and R848 in cytokine release. Therefore, oxyresveratrol can be
able to contrast the synergistic effects of nanoparticles with microorganisms that could be present in
the patient tissues, therefore overcoming a condition unfavorable to the use of some nanoparticles in
biological systems.
Keywords: dendritic cells; oxyresveratrol; cytokines; PLGA nanoparticles; inflammation
1. Introduction
Dendritic cells (DCs) are a heterogeneous cell population endowed with the ability to
phagocytose antigens present in the extracellular environment. Subsequently, DCs undergo
a process of maturation which enables them to present antigens to lymphocytes, thus
activating the specific immune response [1–3]. Mature DCs produce chemical mediators
that modulate the adaptive immune reaction and the inflammatory process to fight cancer
cells and pathogen microorganisms. Among the most important mediators secreted by DCs
there is IL-12, a fundamental cytokine activating natural killer cells and T lymphocytes [4,5],
as well as IL-6 and TNF-α that stimulate the immune cells and are involved in the induction
of the systemic acute phase reaction characterized by fever, headache, changes in the
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sleep-wake cycle, anorexia, nausea and emesis [6,7]. Therefore DCs play a fundamental
role in regulating both inflammatory and adaptive immune response, and a decreased
tolerogenic activity of these cells can promote pathological events such as hypersensitivity
and autoimmunity [8,9]. Interestingly, DC treated with the polyphenol resveratrol during
their differentiation have been reported to became tolerogenic cells showing decreased
ability to stimulate T cells because of a reduced expression of co-stimulatory molecules and
IL-12, and an increased secretion of the immune suppressive cytokine IL-10 [10]. Moreover
oxyresveratrol, a polyphenol derived from Artocarpus lakoocha Roxb.heartwood, a plant
known in Thai as ‘Ma-Haad’ and used in traditional medicine [11], has been shown to exert
anti-inflammatory effects by downregulating the pro-inflammatory cytokine production in
several experimental conditions [12–15]. However, the mechanisms by which polyphenols
exert their anti-inflammatory activity remain to be fully elucidated and, as far as we know,
no investigations have been performed on the effect of oxyresveratrol on the functional
activity of human DCs. This prompted us to examine whether a mechanism by which
oxyresveratrol blunts the inflammation would reside in the inhibition of human DC ability
to produce pro-inflammatory cytokines.
Biodegradable polymeric nanoparticles have been extensively used as delivery sys-
tems of active components such as anticancer drugs, vitamins, proteins, peptides, and
others. There are many advantages using such technology, since polymeric nanoparticles
protect active compounds from degradation, improve their solubility, and promote con-
trolled drug release and targeting [16]. However, the administration of nanostructures to
patients is sometimes hindered by possible side-effects due to their encounter with the cells
of the immune system, which protect the body from foreign intrusions. In fact, the interac-
tion of some nanoparticles with immune cells, including DCs, can cause their activation
and consequently adverse effects such as inflammation or allergy [17,18]. Many different
polymers have been used to produce nanoparticles, but in particular poly(lactic-co-glycolic
acid) (PLGA) has received broad interest because it is biocompatible, biodegradable and
approved for human therapies both by the Food and Drug Administration (FDA) and
the European Medicines Agency (EMA), [19–21]. Therefore, we investigated whether the
insertion of oxyresveratrol into PLGA nanoparticles would modulate the effects of this
polyphenol on DCs.
2. Results
2.1. Synthesis and Characterization of PLGA Nanoparticles
The aim of our investigations was to assess whether oxyresveratrol alone or encapsu-
lated into polymeric nanoparticles would affect the release of proinflammatory cytokines
by human DCs. First, we synthesized PLGA nanoparticles, and we loaded them with
oxyresveratrol. We decided to focus our attention on the encapsulation in PLGA via single
emulsion evaporation method. As illustrated in Table 1, we were able to obtain PLGA
nanoparticles embedding oxyresveratrol showing a diameter quite similar to the one of
empty PLGA nanoparticles, with an average size of 169.6 ± 3.5 and a polydispersity index
(PDI) of 0.06 ± 0.02.
Table 1. Dynamic light scattering and ζ-potential data of unloaded (EMPTY) and oxyresveratrol-
loaded (PLGA(oxy)) poly(lactic-co-glycolic acid) (PLGA) nanoparticles. The results are expressed as
the mean value ± SD of three independent measures on three replica samples.
Nanoformulation Particles Size (nm) Polydispersity Index Z-Potential (mV)
EMPTY 170.2 ± 2.5 0.049 ± 0.040 −9.6 ± 0.4
PLGA(Oxy) 169.6 ± 3.5 0.06 ± 0.02 −7.1 ± 0.5
To further investigate the size distribution of these nanoparticles, Nanotracking and
atomic force microscopy (AFM) analysis were also performed. Figure S1 shows that the
nanoparticle shape was quite spherical and, as it is evident from Table S1, data obtained
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by using three different methods were in agreement and spanned in the same order of
magnitude, even if the techniques were based on different physico-chemical properties.
In addition, the monodispersed trend was observed for both dynamic light scattering
(DLS) and Nanosigtht diagram (Figure S2). The encapsulation of oxyresveratrol did not
affect the size and size-distribution of the nanoparticles, but rather it made the ζ-potential
less negative (−7.1 ± 0.5) than the one of empty nanoparticles (−9.6 ± 0.4) (Table 1);
despite this slight difference, oxyresveratrol loaded nanoparticles showed a good colloidal
stability as well.
The presence of oxyresveratrol in the PLGA nanoformulation was assessed by fluores-
cence spectroscopy. Figure 1a shows the emission pattern of loaded and empty nanopar-
ticles: upon excitation at 335 nm, oxyresveratrol loaded nanoparticles exhibited a fluo-
rescence spectrum different than the one shown by empty nanoparticles. Figure 1b illus-
trates that the emission peak around 410–420 nm of oxyresveratrol encapsulated in PLGA
nanoparticles overlapped the emission spectrum of the free polyphenol in DMSO, and both
these data are indicative of effective entrapment of oxyresveratrol into PLGA nanoparticles.
The observed red-shift trend was probably due to an interaction with the hydrophobic part
of the polymer that could affect the emission pattern.
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Figure 1. (a) Emission spectra of empty PLGA nanoparticles (black line) and oxyresveratrol-loaded PLGA nanoparticles
(red line) collected in phosphate buffer saline pH 7.4. (b) Overlapping between free oxyresveratrol emission pattern in
DMSO (gray line) and oxyresveratrol encapsulated in PLGA nanoparticles (red line).
The encapsulation efficiency for these nanoparticles was found to be close to 45% ± SD;
very similar values, within the experimental error, were obtained using a direct method,
bas d on the quantification of the oxyresveratrol loaded on the nanoparticles, and with the
indirect m thod, where the bound fraction was estimated as the iffere ce between the
total amount added in the reaction buffer and the unloaded fraction still remaining after
the reaction and the two sequent washing steps. The two similar values can be found in
Table S2.
We then investigated whether PLGA nanoparticles released oxyresveratrol at various
time points and temperatures (4 and 37 ◦C) by UV-Visible spectroscopy to understand the
release profile over time in preserving conditions (4 ◦C) and at the temperature used during
the interaction with DCs. We found that oxyresveratrol-loaded nanoparticles exhibited an
initial burst release in the first four hours with a sustained trend i the next 28 h, r aching
a value of 64% in 32 h (Figure 2) As expected, the trends at different temper tures were
similar, even if the increase in temperature led to a curve with an enhanced slope.
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2.3. The Insertion of Oxyresveratrol in PLGA Nanoparticles Inhibited the Synergy between These
Particles and R848 in Induction of Cytokine Release by DCs
We previously demonstrated that the PLGA nanoparticles produced in our laboratory
were efficiently internalized by human monocyte-derived DC [25]. Therefore, we wondered
whether incorporation of oxyresveratrol into these nanoparticles, that can promote its
internalization by cells, would influence the effects of this polyphenol on cytokine secretion
by DCs. First, we checked whether unloaded PLGA particles prepared in our laboratory
would affect the cytokine release by human DCs. Figure 3 shows that the incubation
of resting DCs with 6 or 12 µg of bare PLGA particles did not trigger cytokine release.
However, unloaded PLGA particles significantly and dose-dependently increased the
cytokine secretion by R848-stimulated DCs (Figure 3). These results demonstrate that the
PLGA nanoparticles synthesized following our protocol are unable to interfere per se with
human DC activation mechanisms, but can synergize with agonists of TLR7 and TLR8 in
induction of pro-inflammatory cytokine secretion. The latter event reminds the so-called
“priming effect”, that is the ability of some agents to induce a hyper-responsiveness of
immune cells to other stimuli [26,27]. Figure 3 also shows that the challenge of unstimulated
DCs with 50 and 100 µM oxyresveratrol enclosed into 6 and 12 µg of PLGA nanoparticles
respectively, did not trigger cytokine secretion. Interestingly, oxyresveratrol encapsulated
into PLGA nanoparticles significantly inhibited the synergistic effect of PLGA and R848 in
the induction of IL-12, TNF-α and IL-6 release by DC (Figure 3). Therefore, oxyresveratrol
insertion into nanoparticles can reduce an unwanted pro-inflammatory “priming effect” of
PLGA particles on R848-induced cytokine release by DCs.
2.4. Evaluation of Oxyresveratrol and PLGA Nanoparticle Toxicity on Human DCs
To exclude that our results on cytokine release could be due to toxic effects we exam-
ined whether oxyresveratrol alone or inserted into PLGA nanoparticles would affect the
DC viability. For this purpose, DCs were challenged with free oxyresveratrol, bare PLGA
nanoparticles, or oxyresveratrol-loaded PLGA nanoparticles in absence or presence of R848
as in the experiments depicted in Figure 3 and cell viability was assessed using the Cell
Proliferation Reagent WST-1 assay. Figure 4 shows that in these experimental conditions
the DC viability was not or only slightly altered.
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Figure 4. Effects of free oxyresveratrol and oxyresveratrol-bearing PLGA nanoparticles on DC
viability. DCs were treated or not treated (ctrl) with the indicated doses of free oxyresveratrol (Oxy),
unloaded PLGA nanoparticles (PLGA), or oxyresveratrol-bearing PLGA particles (PLGA + Oxy) for
24 h, followed by 1 h incubation with WST. Values are expressed as the percentage of WST reduction
relative to untreated cells (designated as 100%). Data are means ± SD of four experiments.
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3. Discussion
Many attempts have been made to identify new molecules able to blunt the inflam-
matory response in absence of the harmful side-effects frequently observed following
administration of the currently used glucocorticoids and non-steroid anti-inflammatory
drugs [28,29]. Oxyresveratrol is a polyphenol derived from a plant, Artocarpus lakoocha
Roxb. (Moraceae), which has been used in Thai traditional medicine as an antioxidant
and to treat inflammatory and parasitic diseases [30–32]. Recently, many studies have
been performed to investigate the pharmacological effects of oxyresveratrol: in particular,
it has been reported to suppress lipopolysaccharide-induced inflammatory response in
murine models [31,33,34] and to exert its anti-inflammatory effects mainly by downregu-
lating the release of various cytokines [12–15]. As far as we know, no investigations have
been made on the effect of oxyresveratrol on the functional activity of human DCs, which
play an essential role in activation of inflammation and immune reaction [1–3]. In this
paper we report the results of investigations aimed at clarifying whether a mechanism
by which oxyresveratrol inhibits the inflammation resides in a decreased secretion of
pro-inflammatory cytokines by DCs. Here we show that oxyresveratrol suppressed the
secretion of IL-12, TNF-α and IL-6 by human DCs stimulated with R848, an agonist of
TLR 7 and TLR 8 which recognize single stranded RNA viruses such as Influenza, Sendai,
Coxackie B, HIV and HCV [23,24]. Therefore, cell stimulation with R848 mimics the natural
interaction between DCs and some pathogen viruses, and the results obtained suggest that
oxyresveratrol could be a good tool to mitigate the inflammatory response elicited by these
microorganisms. It is worth to emphasize that here we show that oxyresveratrol inhibited
the R848-induced secretion of cytokines which play a fundamental role in activation of the
inflammatory process. In fact, IL-12 stimulates T cells and natural killer cells to produce
IFN-γ, which in turn widens the immune and inflammatory response [4,5,35], TNF-α medi-
ates basal inflammatory events such as edema, leukocyte adhesion to epithelium, oxidative
stress, and fever [6], and IL-6 activates, among others, acute phase responses, B lymphocyte
maturation, and T cell functions [7]. Therefore, oxyresveratrol might be a useful tool to treat
autoimmune and chronic inflammatory diseases, such as inflammatory bowel diseases,
psoriasis, ankylosing spondylitis, multiple sclerosis, asthma, Crohn’s disease, ulcerative
colitis, Alzheimer’s diseases and rheumatoid arthritis, in which IL-12, TNF-α, and IL-6
have been found to play an important role [7,36–39].
Then we wondered whether the effects of oxyresveratrol on R848-stimulated DCs
could be enhanced by its insertion into particles that promote its internalization by DCs. It is
well known that PLGA particles are efficiently ingested by human DCs [40–42]. Therefore,
we synthesized empty and oxyresveratrol-loaded PLGA nanoparticles showing similar
dimensions, both resulting in a monodispersed suspension in phosphate buffer saline
(PBS), and having good colloidal stability. The encapsulation efficiency was close to 45%,
and the release of oxyresveratrol by nanoparticles at 37 ◦C reached 64% in 32 h, ensuring
to oxyresveratrol a good biodisponibility in the 24 h of exposure to dendritic cells. We
previously showed that the PLGA nanoparticles produced in our laboratory were easily
internalized by human monocyte-derived DCs, as demonstrated by confocal microscopy
experiments [25]. Therefore, these PLGA nanoparticles represented a very good tool to
carry oxyresveratrol inside the DCs.
The use of particles for medical purposes is often hampered by the ability of some
of them to activate immune cells, thus leading to pro-inflammatory effects and adverse
reactions such as fever, allergy or autoimmunity [17,18,43]. Therefore, we assessed whether
PLGA nanoparticles produced in our laboratory induced per se DC activation. Here
we show that both bare and oxyresveratrol-loaded PLGA nanoparticles were unable to
activate cytokine release by resting DCs suggesting that these particles are biologically inert.
However, bare PLGA enhanced the cytokine release triggered by DC stimulation with
R848. We do not know the reasons of this unexpected pro-inflammatory effect. It might be
due to the ability of PLGA nanoparticles to interact with unknown cellular targets able to
cooperate with TLR7- and TLR8-dependent pro-inflammatory signals. As an alternative,
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the activation of phagocytosis mechanisms to engulf the PLGA particles might elicit
pathways which collaborate with those induced by R848 to enhance cytokine release.
This synergistic effect reminds the event named “cell priming”, characterized by the
ability of some agents to induce an hyper-responsiveness of leukocytes to other stimuli
if simultaneously or consequently added [26,27]. In this regard, it has been previously
demonstrated that the microbial chemoattractant formyl-methionine-leucil phenylalanine
(f-MLP) synergized the ability of ORMOSIL nanoparticles to induce the release of cytokines
by human leukocytes [44]. Moreover, it has been reported that simultaneous addition of
LPS and porous silicon-TiO2 microparticles was much more effective than stimulation
with LPS alone to induce IL-12 and TNF-α secretion by human DCs [45]. Therefore, a
synergistic effect between nanoparticles and molecules of microorganisms seems not to be
a rare and unexpected result, although it is scantly investigated by researchers dealing with
nanostructures. Whichever is the case, here we show that association of oxyresveratrol to
PLGA nanoparticles blunted the PLGA nanoparticle-dependent enhancement of cytokine
release by R848 treated DCs, indicating that this polyphenol maintains its anti-inflammatory
properties also once conjugated to a nanostructure and, interestingly, that it could render a
nanostructure less dangerous, in particular when administered in the presence of some
microorganisms such as viruses. The mechanism by which oxyresveratrol inhibits the
secretion of cytokines by human DCs remains to be clarified. However, on the basis of
previous reports showing that this polyphenol decreased the release of cytokines from
HMC3 human microglial and RAW 264.7 murine macrophage cell lines through inhibition
of phosphatidylinositol 3-kinase [15,31], it is conceivable that a similar mechanism might
also take place in human DCs.
In summary, our data indicate that a nanoparticle such as PLGA, having no apparent
intrinsic pro-inflammatory activity, could participate to activation of pro-inflammatory
events when administered in the presence of other unexpected agents, such as pathogens or
their derivatives. At present, we have no explanation of the reason of this strange behavior,
but the obtained results indicate that the interactions taking place among immune cells,
nanostructures and microorganisms can be more complex than expected. The identification
of the mechanisms involved in this effect went beyond the scope of the present work and
will be the matter of future studies. Nevertheless, our data highlight the importance of an
accurate and complete testing of both loaded and unloaded nanostructures in combination
with products of microorganisms to avoid unwanted side-effects once they are administered
to patients. Importantly, here we show that oxyresveratrol is a very good anti-inflammatory
agent, which inhibits pathogen-induced inflammatory events, but can also mitigate an
eventual synergistic effect between nanostructures and products of microorganisms when
it is enclosed into such nanostructures. We have previously shown that PLGA-associated
α-bisabolol, a natural sesquiterpene found in the oil of Matricaria chamomilla, decreased
the secretion of cytokines by lipopolysaccharide (LPS)-stimulated human DCs [25]. These
results, combined with those reported here, indicate that PLGA nanoparticles represent a
good tool for carrying plant-derived molecules in order to inhibit the pro-inflammatory
activity of DCs.
4. Materials and Methods
4.1. Materials
RPMI 1640 and low-endotoxin FBS were obtained from Lonza (Walkersville, MD,
USA). Recombinant human GM-CSF and human IL-4 were purchased from Miltenyi
Biotec (Bergisch Gladbach, Germany); Flow cytometric analysis was performed using
the following mouse anti-human antibodies: CD83 (HB15e) and CD1a (HI149) (Becton
Dickinson, San Jose, CA, USA); CD80 (2D10), CD86 (T2.2), HLA-DR (L243) and CD14
(M5E2) (Biolegend, San Diego, CA, USA). PLGA (poly[DL-lactide-co-glycolide] 50:50
lactide-glycolide ratio, CAS 26780-50-7), PVA (poly[vinyl alcohol], CAS 9002-89-5), Acetone
(≥99% purity, 1.00013), Dimethyl sulfoxide (DMSO, ≥99% purity D-5879), Oxyresveratrol
(≥97% purity, 91211) were purchased from Sigma-Aldrich, (St. Louis, MO, USA).
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4.2. Preparation of PLGA Nanoparticles
The protocol used for the production of PLGA nanoparticles loading oxyresveratrol is
based on single emulsion-evaporation method, under sterile conditions at 20 ◦C [19,46].
10 mg of the polymer and 5 mM (1.22 mg) of oxyresveratrol from Artocarpus lakoocha
heartwood were co-dissolved in 1 mL of organic solvent (95% Acetone and 5% DMSO);
the obtained organic phase was added dropwise under stirring (2000 RPM) to 10 mL of
1% polyvinyl alcohol (PVA) aqueous solution and left overnight to evaporate the organic
phase. Afterwards, the preparation was pelleted at 4 ◦C 11,000 rpm for 20 min (Eppendorf
Centrifuge 5804R) and nanoparticles were collected and washed twice with 10 mL of
Milli-Q water. Finally, purified nanoparticles were re-suspended in 1 mL of phosphate
buffer saline solution pH 7.4 for the subsequent analysis and storage at 4 ◦C, otherwise
freeze-dried. Empty PLGA nanoparticles were prepared with the same protocol avoiding
the addiction of oxyresveratrol to the organic phase.
4.3. Size and ζ-Potential Characterization
Size and ζ-potential of PLGA nanoparticles were estimated at 25 ◦C using a Nano Zeta
Sizer ZS (ZEN3600, Malvern Instruments, Malvern, Worcestershire, UK). Samples were
resuspended in PBS, being used as a stock suspension, and were diluted 10 times from
the stock solutions in PBS for size determination and into in 10 mM NaClO4 pH 7.5 for
ζ-Potential measurements; data were collected in triplicate and analyzed by the ZetaSizer
software (version 7.10).
To further support DLS data, a Nanosight tracking analysis was performed on
PLGA(Oxy) NPs and empty PLGA nanoparticles (Malvern NanoSight NS300, Malvern
Panalytical Ltd, Malvern, UK). Due to the high concentration, each sample was diluted
5000 times in PBS; 1498 frames divided in 3 runs of 60 s were recorded at camera level of
13 and the analysis were performed with a detection threshold in the range 5–7. Finally,
the number of particles/mL was estimated as well.
Moreover, pictures of atomic force microscopy of both nanoparticle types were ac-
quired: 20 µL of each sample (prepared as in the above section) were loaded on a bracket
covered by inert mica surface. After 20 min for solvent evaporation, the analysis was
performed using a NT-MDT Solver Pro atomic force microscope (Moscow, Russia) with
NT-MDT NSG01 golden coated silicon tip in semi contact mode with different scanning
frequencies (3–1 Hz) in order to produce optimized AFM images. The microscope was cali-
brated by a calibration grating (TGQ1 from NT-MDT) in order to reduce nonlinearity and
hysteresis in the measurements. Finally, images were processed with the Scanning Probe
Image Processor (SPIPTM) program (Image Metrology ApS, version 5.13, Lyngby, Den-
mark) and a statistical study was performed to compare results to DLS and Nanosight data.
4.4. Spectroscopic Studies, Encapsulation Efficiency and Release Evaluation
To assess the presence of oxyresveratrol inside our nanoparticles the emission pattern
was recorded upon excitation at 335 nm, the absorption wavelength of the polyphenol, by
using a Jasco Spectrofluorometer FP-8200 (Easton, MD, USA).
To quantify the amount of the entrapped oxyresveratrol (Encapsulation efficiency (EE)),
a direct method was used. PLGA(Oxy) NPs were dissolved in DMSO and the obtained
solution was analyzed using a calibration curve (Supplementary Materials Figure S3a).





To confirm this data a second method has been employed as well: waste supernatants
from the nanoparticle preparation were collected and analyzed by comparing data to a
second calibration curve obtained in Milli-Q water (Figure S3b). OxyRloaded was indi-
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rectly estimated by the following Equations (2) and (3) and finally EE was calculated as
described above.
OxyRloaded = OxyRfed − OxyRlost (2)
OxyRlost = OxyRSupernatant1 + OxyRwash1 + OxyRwash2 (3)
To assess the ability of the nanoparticles to retain oxyresveratrol over the time, a
release study was performed in 1 mL of PBS pH 7.4 at 4 and 37 ◦C. Samples were collected
at different time intervals and replaced with an equal volume of media to maintain the
sink condition. The released OxyR was quantified using a calibration curve obtained by
UV-Visible spectroscopy at 335 nm.
4.5. DC Preparation and Culture
After written informed consent and upon approval of the ethical committee (Prot.
N. 5626, 2 February 2012; Prot. n. 57182, 16 October 2019), buffy coats from the venous
blood of normal healthy volunteers were obtained from the Blood Transfusion Centre
of the University of Verona. Peripheral blood mononuclear cells were isolated by Ficoll-
Hypaque and Percoll (GE Healthcare Life Science) density gradients and used as a source
for immunomagnetic isolation of CD14-positive cells (Miltenyi Biotec GmbH). The purity
of CD14+ cells was always greater than 98%, as determined by flow cytometry. To generate
immature DCs, monocytes were cultured at 37 ◦C, 5% CO2 at 1 × 106/mL in 6-well tissue
culture plates (Greiner, Nurtingen, Germany) in RPMI-1640 supplemented with 10% FBS
(<0.5 EU/mL; Sigma-Aldrich, (St. Louis, MO, USA), 2 mM L-glutamine, 50 ng/mL GM-
CSF and 20 ng/mL IL-4. After 5 days, non-adherent immature DCs were harvested and
characterized by flow cytometry as CD1ahigh, CD80−, CD83−, CD86low and HLA-DRlow.
To induce cytokine release, DCs were stimulated for 24 h with 5 µM R848 (Invivogen).
4.6. Quantification of Cytokine Production
ELISA development kits purchased from Mabtech (Nacka Strand, Sweden) were used
to assay the protein levels of IL-12 (p70) (range 6–600 pg/mL), IL-6 (range 10–1000 pg/mL)
and TNF-α (range 4–400 pg/mL) in the cell culture supernatant, according to the man-
ufacturer’s instructions. Briefly, DCs resting or activated with 5 µM R848 were treated
with oxyresveratrol alone or encapsulated in PLGA nanoparticles, or with corresponding
amounts of bare PLGA particles for 24 h, and then the supernatants were collected. Several
dilutions of each supernatant were incubated for 2 h at room temperature protected from
the light in appropriate assay plates (EIA/RIA Plate, 96 Well Half Area, Flat Bottom, High
Binding purchased from Corning (Corning, NY, USA) previously coated overnight at 4 ◦C
with 50 µL/well Capture Antibody and then blocked by addition of 100 µL/well Assay
Diluent for 1 h at RT. Supernatants were discarded and Detection Antibody (50 µL/well)
was added. After 1 h incubation at RT, Avidin-HRP (50 µL/well, 30 min) and subsequently
Substrate Solution (50 µL/well, 15 min), were added. The reaction was stopped with Stop
Solution. Every step of the above procedure was followed by appropriate plate washes. The
plates were read at 450 nm with Victor3 1420 Multilabel Counter PerkinElmer. A standard
curve was prepared by serial dilution of standards and used for determining the cytokine
concentrations in supernatants.
4.7. Cell Viability Evaluation
Cell viability was assessed using the Cell Proliferation Reagent WST-1 assay (Roche
Diagnostics GmbH, Mannheim, Germany) according to the manufacturer’s instructions.
DCs resting or activated with R848 were treated with oxyresveratrol alone or encapsulated
in PLGA nanoparticles, or with corresponding amounts of bare PLGA particles for 24 h.
After treatment, cell supernatant was removed and 50 µL of pre-warmed fresh complete
medium were added to the cells and to 3 empty wells (Blank). A 2× WST solution
was freshly prepared by dilution of the 10× WST reagent in the complete medium and
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a volume of 50 µL was dispensed in the wells and blank. The plate was incubated for
60 min. The absorbance (OD) of the samples was measured using a Victor3 multilabel
reader (PerkinElmer, Shelton, CT, USA) at 450 nm.
4.8. Statistical Analysis
Data are expressed as means + SD. Statistical analyses, including two-way ANOVA
followed by Bonferroni post-test, were performed with GraphPad Prism 5 (GraphPad
Software, Inc., San Diego, CA, USA).
5. Conclusions
An important contribution of our findings is the concept that interaction of nanos-
tructures with immune cells could lead to unexpected effects, in particular if microor-
ganisms are presents in the tissues of patients to whom nanoparticles are administered.
As evidenced when analyzing the IL-12, IL-6 and TNF-α release, PLGA nanoparticles
can potentiate the pro-inflammatory effect exerted by R848, an agonist recognizing some
virus-sensing receptors, on human DCs. However, the inclusion of oxyresveratrol into
PLGA nanoparticles had an inhibitory effect on this synergistic mechanism, making the
nanoparticles less dangerous. These data, although limited to IL-12, IL-6 and TNF-α, which
are anyway fundamental mediators of inflammation [4–7], indicate that oxyresveratrol, in
addition to carrying out an anti-inflammatory effect on virus-stimulated DCs, once inserted
into particles can render them more biocompatible. In conclusion here we show that
oxyresveratrol represents a useful molecule to inhibit the activity of human DCs. Owing to
the essential role of DCs in the regulation of the inflammatory and immune reaction, we
believe that the results of our investigation could be useful for a possible future translation
into the clinical practice of anti-inflammatory and immunosuppressive therapy.
Supplementary Materials: The following are available online, Figure S1: AFM image of a single
oxyresveratrol-loaded PLGA nanoparticle with a resolution of 2.5 × 2.5 µm (a). Image of several
single loaded nanoparticles and an aggregate with a resolution of 20 × 20 µm (b). The images
were collected in intermittent mode. Figure S2: DLS Number diagram (a) and Nanosight tracking
analysis diagram (b) of oxyresveratrol-loaded PLGA nanoparticles. Measurements where performed
in triplicate. Figure S3: Calibration curve for oxyresveratrol in DMSO (a). Calibration curve for
oxyresveratrol in aqueous solution (b). Table S1. Comparison between DLS, AFM and Nanosight
tracking analysis data for empty and oxyresveratrol loaded nanoparticles. Table S2. Comparison
between encapsulation efficiency value calculated directly breaking the nanoparticles and the same
value indirectly estimated.
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